News | May 14, 2007

Confirmatory Trial Developed for Acorn’s Cardiac Support Device

May 15, 2007 — Acorn Cardiovascular has announced that the FDA will consider approval of the CorCap Cardiac Support Device (CSD) based on the successful completion of a prospective confirmatory trial that addresses issues raised by the Medical Device Dispute Resolution Panel and the Circulatory System Devices Panel. The company had completed a 300-patient prospective, randomized pivotal trial and submitted data to the FDA in 2004. However, the two panels voted against approval for the CorCap CSD in December 2006 and June 2005, respectively, citing the need for additional clinical data.

Since the MDDRP decision last year, Acorn Cardiovascular has worked closely with Dan Schultz, M.D., director of the Center for Devices and Radiological Health (CDRH), and Bram Zuckerman, M.D., director of the Division of Cardiovascular Devices, to design a confirmatory trial that would alleviate the concerns of the panels. Dr. Schultz is the highest-ranking official at FDA with responsibility for the assessment of medical devices.

The confirmatory trial will assess a patient population that demonstrated the greatest clinical benefit in the pivotal trial. If Acorn meets the success criteria for the confirmatory trial, it is expected that FDA may be able to approve the device without engaging a third advisory panel. It will involve 50 patients in key investigational sites selected from the original 29 pivotal trial site locations.

Dr. Michael A. Acker, chief of the Division of Cardiac Surgery at the University of Pennsylvania, will serve as principal investigator (PI) of the confirmatory trial. Sites should start enrolling patients in summer 2007, with the aim of completing enrollment in early 2008. Following a six-month follow-up period and pending positive results, the company anticipates approval to occur by the end of 2008 or the beginning of 2009.

For more information visit www.acorncv.com.

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init